Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
Bristol-Myers Squibb
Summary
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria * Signed Written Informed Consent. * Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study. * On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study. * WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF. Exclusion Criteria * Participant is not eligible for study treatment per the…
Interventions
- DrugNivolumab
Specified dose on specified days
- DrugIpilimumab
Specified dose on specified days
- DrugCabozantinib
Specified dose on specified days
- DrugTrametinib
Specified dose on specified days
- DrugRelatlimab
Specified dose on specified days
- DrugNivolumab + Relatlimab
Specified dose on specified days
- DrugCapecitabine
Specified dose on specified days
Locations (399)
- Local Institution - 0220Huntsville, Alabama
- University of Arizona College of MedicineTucson, Arizona
- Innovative Clinical Research InstituteLynwood, California
- Local InstitutionSan Francisco, California
- Local Institution - 0099San Francisco, California
- Local Institution - 0233Aurora, Colorado